[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

Arrowhead Research Corporation (ARWR)

Arrowhead Pharmaceuticals hits a 52-week high driven by FDA Breakthrough Designation for Plozasiran and a Novartis collaboration, with significant increases in trading volume and social media buzz.

About Arrowhead Research Corporation

Arrowhead Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing gene-silencing medicines for intractable diseases.
Arrowhead Research Corporation uses the ticker $ARWR for trading. Listed in the Stocks category within the Healthcare sectors.

Insights

Arrowhead Research Corporation (ARWR) trading volume is up XXXXXX% from the previous month.
Arrowhead Research Corporation Price hit a 52-Week high of $XXXXX for the hour

Price: $XXXXX

Price 24-Hour Time-Series Raw Data
The stock has surged to a 52-week high, driven by positive news such as the FDA Breakthrough Therapy Designation for Plozasiran and the Novartis collaboration. Increased social media mentions and trading volume further support this upward momentum, despite some lingering valuation concerns.

24-Hour: XXXX% 7-Day: XXXXX% 30-Day: XXXXX%

1-Year High: $XXXXX on 2025-12-11
1-Year Low: $XX on 2025-04-08

AltRank: XXX

AltRank Line Chart
AltRank 24-Hour Time-Series Raw Data
Arrowhead Research Corporation (ARWR) is currently AltRank #247 based on combined combined social and market metrics Daily Average: XXX
X Week: XXX +142
X Month: XXX -XXX
X Months: XXX -XXXXX
X Year: XXX +148
1-Year High: XXXXX on 2025-05-30
1-Year Low: XX on 2025-09-03

Galaxy Score: XXXXX

Galaxy Score Line Chart
Galaxy Score 24-Hour Time-Series Raw Data
Current Value: XXXXX
Daily Average: XX
X Week: XX -X
X Month: XX -X
X Months: XX +1
X Year: XX +2
1-Year High: XX on 2025-09-02
1-Year Low: XX on 2025-09-16

Engagements: XXXXXX (24h)

Engagements Line Chart
Engagements 24-Hour Time-Series Raw Data
Current Value: XXXXXX
Daily Average: XXXXXX
X Week: XXXXXXX -XX%
X Month: XXXXXXXXX +362%
X Months: XXXXXXXXX +108%
X Year: XXXXXXXXX +61%
1-Year High: XXXXXXX on 2025-11-25
1-Year Low: XXXXX on 2025-05-17

Engagements by network (24h): X: XXXXXX YouTube: XX

Mentions: XXX (24h)

Mentions Line Chart
Mentions 24-Hour Time-Series Raw Data
Current Value: XXX
Daily Average: XXX
X Week: XXX -XX%
X Month: XXXXX +163%
X Months: XXXXX +99%
X Year: XXXXX +96%
1-Year High: XXX on 2025-11-28
1-Year Low: XX on 2025-06-14

Mentions by network (24h): X: XXXXX YouTube: X

Creators: XXX (24h)

Creators Line Chart
Creators 24-Hour Time-Series Raw Data
XXX unique social accounts have posts mentioning Arrowhead Research Corporation (ARWR) in the last XX hours which is down XXXX% from XXX in the previous XX hours Daily Average: XX
X Week: XXX -XX%
X Month: XXX +251%
X Months: XXXXX +157%
X Year: XXXXX +71%
1-Year High: XXX on 2025-06-28
1-Year Low: XX on 2025-04-28

The most influential creators that mention Arrowhead Research Corporation in the last XX hours

Creator	Rank	Followers	Posts	Engagements
@BiomedicalRX	X	XXXXX	X	XXXXX
@BioBoyScout	X	XXXXX	X	XXXXX
@BikeRieder	X	XXXXX	X	XXXXX
@pikva63	X	X	X	XXX
@Hall8Jack	X	XXXXX	X	XXX
@smiuffy	X	XXXXX	X	XXX
@SuperDuperDrugs	X	XXX	X	XXX
@RNAiAnalyst	X	XXXXXX	X	XXX
@Tickeron	X	XXXXXX	XX	XXX
@StockMKTNewz	XX	XXXXXXX	X	XXX

Sentiment: XX%

Sentiment Line Chart
Sentiment 24-Hour Time-Series Raw Data
Current Value: XX%
Daily Average: XX%
X Week: XX% -XX%
X Month: XX% -XX%
X Months: XX% -XX%
X Year: XX% -XX%
1-Year High: XXX% on 2025-06-12
1-Year Low: XX% on 2025-03-20

Most Supportive Themes:

Novartis Deal: (10%) Arrowhead Pharmaceuticals announced the closing of its global license and collaboration agreement with Novartis, receiving an upfront payment and shifting development risk for the ARO-SNCA program.
Pipeline Progress & Data: (15%) Discussions highlight promising pipeline progress, including potential data releases for programs like ARO-C3 and ARO-MMP7, and comparisons with competitors like Wave Life Sciences (WVE).
RNAi Technology Focus: (20%) The community is actively discussing the strengths and potential of RNAi therapies, with comparisons to other gene-editing technologies like CRISPR and mentions of Arrowhead's leadership in the space.

Most Critical Themes:

Valuation Concerns: (5%) Some posts question Arrowhead's current valuation, especially in comparison to companies with commercialized drugs, despite its extensive pipeline.
Competitive Landscape: (10%) The competitive nature of the RNAi and broader biotech space is frequently mentioned, with comparisons to companies like Sarepta Therapeutics (SRPT), Ionis Pharmaceuticals (IONS), and Alnylam Pharmaceuticals (ALNY).

Social Dominance: XXXXX%

Social Dominance Line Chart
Social Dominance 24-Hour Time-Series Raw Data
Current Value: XXXXX%
Daily Average: XXXXX%
X Week: XXXXX% -XXXXXXXXXXXXXXXXXXXXX%
X Month: XXXXX% +0.022%
X Months: XXXXX% +0.031%
X Year: XXXXX% -XXXXX%
1-Year High: XXXXX% on 2025-01-02
1-Year Low: XXXXXX% on 2025-06-14

Market Dominance: XXXXX%

Market Dominance Line Chart
Market Dominance 24-Hour Time-Series Raw Data
Current Value: XXXXX%
Daily Average: X%
1-Year High: XXXXX% on 2025-12-08
1-Year Low: XXXXX% on 2025-12-11

Market Cap: $XXXXXXXXXXXXX

Market Cap Line Chart
Market Cap 24-Hour Time-Series Raw Data
Current Value: $XXXXXXXXXXXXX
Daily Average: $XXXXXXXXXXXXX
X Week: $XXXXXXXXXXXXX +$9.30%
X Month: $XXXXXXXXXXXXX +$68%
X Months: $XXXXXXXXXXXXX +$342%
X Year: $XXXXXXXXXXXXX +$240%
1-Year High: $XXXXXXXXXXXXX on 2025-12-11
1-Year Low: $XXXXXXXXXXXXX on 2025-04-08